original ) (raw )A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS
Abby Li
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012
View PDFchevron_right
Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalizations for respiratory syncytial virus in infants
Meri Gorgievski-hrisoho , Andrea Duppenthaler
Swiss medical weekly: official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology
View PDFchevron_right
Palivizumab Prophylaxis of Respiratory Syncytial Virus Infection in High‐Risk Infants: A Note of Caution
Laurie Debonnett
Journal of Paediatrics and Child Health, 2003
View PDFchevron_right
Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study
Yuh-jyh Lin
Pediatric Research
View PDFchevron_right
A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan
Li-min Huang
2014
View PDFchevron_right
Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
Valeria Belleudi
BMJ Paediatrics Open, 2021
View PDFchevron_right
Passive immunisation of preterm infants with palivizumab against RSV infection
Nicholas Embleton
Journal of Infection, 2006
View PDFchevron_right
Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
Dr. Khaled El-Atawi
Canadian Respiratory Journal, 2019
View PDFchevron_right
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
Nusrat Homaira
International Journal of Pediatrics, 2014
View PDFchevron_right
Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants
Meri Gorgievski-Hrisoho
Swiss medical weekly, 2001
View PDFchevron_right
Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
Jesse Papenburg
Journal of the Pediatric Infectious Diseases Society, 2020
View PDFchevron_right
Beyond randomized controlled trials: A “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab
Ian Mitchell
Pediatric Pulmonology, 2006
View PDFchevron_right
Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab
Dominic Fitzgerald
Paediatric Respiratory Reviews, 2009
View PDFchevron_right
One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
Maria Elina Serra
Jornal de pediatria, 2017
View PDFchevron_right
Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit
Daniel Virella
Journal of Hospital Infection, 2004
View PDFchevron_right
Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
Gary M Ginsberg
Israel Journal of Health Policy Research, 2018
View PDFchevron_right
Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
Dan Stewart
BMC Infectious Diseases, 2013
View PDFchevron_right
Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
Neal Thomas
Biologics Targets Therapy, 2007
View PDFchevron_right
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis
Luba Nalysnyk
Pediatric Critical Care Medicine, 2011
View PDFchevron_right
Use of palivizumab with other infection control measures to control respiratory syncytial virus outbreaks in neonatal care units
Majeda Hammoud
Journal of Tropical Pediatrics, 2016
View PDFchevron_right
Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven...
Andrea Wolfler
Italian Journal of Pediatrics
View PDFchevron_right
Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
Sabina Terzic
2016
View PDFchevron_right
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
Krista Lanctôt
European Journal of Pediatrics, 2011
View PDFchevron_right
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Sinsi Hernández-Cancio
PEDIATRICS
View PDFchevron_right
Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant
Phillip Wozniak
American Journal of Perinatology, 2019
View PDFchevron_right
RSV hospitalisation and healthcare utilisation in moderately prematurely born infants
Janet Peacock
European Journal of Pediatrics, 2012
View PDFchevron_right
The assessment of future RSV immunizations: How to protect all infants?
Catherine Weil-olivier
Frontiers in Pediatrics
View PDFchevron_right
An update of the recommendations of the spanish neonatology society for the use of paivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants
Cèsar W. Ruiz-Campillo
Anales de Pediatría (English Edition), 2019
View PDFchevron_right